Search

BI Access to Healthcare Strategy_Availability

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.

Exploring innovation in interstitial lung disease (ILD)

Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.

Why cancer care is personal for us

At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.

Award: Boehringer Ingelheim is Global Top Employer 2022

Global Top Employer 2022

New spesolimab data show significant improvement in GPP flares

Boehringer Ingelheim reaches more patients than ever, innovation drives growth

Boehringer Ingelheim reports a strong performance in 2022.

Boehringer acquires T3 Pharma

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

DCRI-collaboration-empact-mi

Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction

AI&Data Science Fellowship Tuebingen

Celebrating 20 years of Metacam for cattle

Celebrating 20 years of Metacam (Meloxicam) for cattle

Retinal health: All eyes on vision loss

Discover how we want to prevent vision loss caused by diabetic retinopathy and other retinal diseases

Phase II clinical trial weight loss results

Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)

Covid Global Support Programm

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

preventive care cat veterinarian

What can we all, cat owners or veterinarians, do to promote cat health? Click to find out!

Animal Health Collaboration with Novozymes

Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global poultry production. Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product f

Discover your hidden talent with BI Open – the new platform for data science enthusiasts

Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.

Global Top Employer 2023

Phase 3 studies survodutide obesity and overweight

Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease

Partnership Boehringer Ingelheim Lifebit health data

Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data

Women in STEM 2022

Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.

DiaTEC new purification technology Ingelvac CircoFLEX

Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®

Partnering with Constantia Flexibles for augmented reality

Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.

Investment social engagements in Cowtribe veterinary startup

Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements

additional-investment-in-Lyon-Jonage

Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France

Making-more-health-together-2021

1,200 participants from around the world join virtual convention on November 11-12

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers